Back to top
more

Meridian Bioscience Inc. (VIVO)

(Delayed Data from NSDQ)

$11.51 USD

11.51
1,168,817

-0.48 (-4.00%)

Updated May 3, 2019 04:00 PM ET

After-Market: $11.50 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Meridian Bioscience (VIVO) Stock Sinks As Market Gains: What You Should Know

Meridian Bioscience (VIVO) closed at $24.49 in the latest trading session, marking a -1.84% move from the prior day.

Meridian Bioscience (VIVO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Meridian Bioscience (VIVO) Stock Outpacing Its Medical Peers This Year?

Is (VIVO) Outperforming Other Medical Stocks This Year?

Chembio Diagnostics (CEMI) Surges: Stock Moves 12.1% Higher

Chembio Diagnostics (CEMI) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.

BioLife (BLFS) Catches Eye: Stock Jumps 12.1%

BioLife (BLFS) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.

The Zacks Analyst Blog Highlights: Galiano Gold, Fortinet, Meridian Bioscience, Crescent Capital BDC and NextEra Energy

The Zacks Analyst Blog Highlights: Galiano Gold, Fortinet, Meridian Bioscience, Crescent Capital BDC and NextEra Energy

Exagen (XGN) in Focus: Stock Moves 7.9% Higher

Exagen (XGN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zacks.com featured highlights include: eXp World, Lakeland Industries, Meridian Bioscience, Kiniksa Pharmaceuticals and iClick Interactive Asia Group

Zacks.com featured highlights include: eXp World, Lakeland Industries, Meridian Bioscience, Kiniksa Pharmaceuticals and iClick Interactive Asia Group

Sreoshi Bera headshot

5 Stocks to Wade Through Hurdles in Second-Half 2020

Keeping the coronavirus impact in mind, we have shortlisted five stocks that can return well on investment in the second half of 2020.

Nalak Das headshot

5 Stocks With Recent Price Strength Amid Spike in Coronavirus

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for June 24th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Meridian Bioscience (VIVO) Soars to 52-Week High, Time to Cash Out?

Meridian Bioscience (VIVO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Panel Of Zacks Experts headshot

Top Stock Picks for Week of May 11, 2020

Two Medical Products Stocks with Recent Price Strength.

Meridian Bioscience (VIVO) Q2 Earnings and Revenues Surpass Estimates

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 187.50% and 0.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Meridian Bioscience (VIVO) Beats Q1 Earnings Estimates

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 66.67% and -2.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Meridian Bioscience (VIVO) Q4 Earnings and Revenues Surpass Estimates

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 44.44% and 1.03%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should Value Investors Pick Meridian Bioscience (VIVO) Now?

Let's see if Meridian Bioscience (VIVO) stock is a good choice for value-oriented investors right now from multiple angles.

Meridian Bioscience (VIVO) Beats Q3 Earnings Estimates

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 60.00% and -2.76%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Meridian Bioscience (VIVO) Q2 Earnings and Revenues Top Estimates

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 26.67% and 0.46%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Meridian Bioscience (VIVO) to Report a Decline in Earnings: What to Look Out for

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Buy Masimo (MASI) Stock Right Now

Masimo (MASI) announces CE marking of its Next Generation SedLine brain function monitoring for pediatric patients.